Home » FDA Expands Label for Roche Cobas EGFR Companion Diagnostic

FDA Expands Label for Roche Cobas EGFR Companion Diagnostic

Sep 29, 2016
|
staff reporter

NEW YORK (GenomeWeb) – The US Food and Drug Administration has expanded the labeling for Roche's Cobas EGFR Mutation Test v2 as a companion diagnostic that can analyze plasma samples from non-small cell lung cancer patients considering treatment with AstraZeneca's Tagrisso (osimertinib). 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

Out of the Books

NPR reports that Turkish high school students will no longer study evolution.

Mountainside Sequencing

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

Better Treatments Sought

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

This Week in PNAS

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.

What's Popular?

In Molecular Diagnostics

  1. Insurers Turn to Automated Prior Authorization Programs to Rein in Genetic Testing Use

    Premium

  2. LabCorp, OmniSeq Sign Distribution Deal

  3. TJU-Led Team Wins $2.7M NCI Grant to Study Circulating Tumor Cells in Breast Cancer

  4. LabCorp Distribution Deal Allows OmniSeq to Focus on Studying Utility of Molecular Tests

    Premium

  5. Diagenode to Commercialize Clinical Breast Cancer Test Based on New Epigenetic Signature

    Premium

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.